Cite

HARVARD Citation

    Rubinstein, M. et al. (2020). Phase 2 study of LY3023414 in patients with advanced endometrial cancer harboring activating mutations in the PI3K pathway. Cancer. 126 (6), pp. 1274-1282. [Online]. 
  
Back to record